title: Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer.
abstract: BACKGROUND
  Huachansu, a Chinese medicine that comes from dried toad venom from the skin glands of Bufo gargarizans or B. melanostictus, has been used in the treatment of various cancers in China. The authors conducted a pilot study, using a phase 1 trial design, of huachansu in patients with advanced cancer.
  
  
  METHODS
  Huachansu was administered intravenously for 14 days followed by 7 days off (1 cycle). Without significant adverse events or progressive disease, treatment continued beyond 2 cycles. The dose of huachansu was escalated as follows with 3 patients per cohort: 10 (level 1), 20 (level 2), 40 (level 3), 60 (level 4), and 90 (level 5) mL/m(2).
  
  
  RESULTS
  Fifteen patients (hepatocellular cancer, n = 11; nonsmall cell lung cancer, n = 2; pancreatic cancer, n = 2) were enrolled in the trial, and no dose-limiting toxicities (DLTs) were found. Eleven patients had no drug-related toxicity greater than grade 1. Six (40%) had stable disease (median duration, 6.0 months; range, 3.5-11.1 months). One of these patients (with hepatocellular cancer) had 20% regression (duration, 11 months) (dose level 1). Quality of life improved for patients with stable disease. Plasma bufalin concentration reached maximal levels at the end of the 2-hour infusion and was proportional to the amount of drug being administered (0.81-3.38 ng/mL).
  
  
  CONCLUSIONS
  No DLT was observed with the use of huachansu at doses up to 8x higher than typically used in China. Six patients had prolonged stable disease or minor tumor shrinkage.
authors.affiliation: International Center of Integrative Oncology, Fudan University Cancer Hospital, Shanghai, China.
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Meng
authors.forename: Peiying
authors.initials: P
authors.lastname: Yang
authors.forename: Yehua
authors.initials: Y
authors.lastname: Shen
authors.forename: Wenying
authors.initials: W
authors.lastname: Bei
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yongqian
authors.initials: Y
authors.lastname: Ge
authors.forename: Robert A
authors.initials: RA
authors.lastname: Newman
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Cohen
authors.forename: Luming
authors.initials: L
authors.lastname: Liu
authors.forename: Bob
authors.initials: B
authors.lastname: Thornton
authors.forename: David Z
authors.initials: DZ
authors.lastname: Chang
authors.forename: Zongxing
authors.initials: Z
authors.lastname: Liao
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000368:Aged; D000664:Amphibian Venoms / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects
chemical_list: D000664:Amphibian Venoms; D000970:Antineoplastic Agents; C545813:huachansu
references.citation: Oncogene. 1999 Apr 15;18(15):2413-21
references.pmid: 10229192
references.citation: Cancer. 2000 Oct 1;89(7):1634-46
references.pmid: 11013380
references.citation: J Nat Prod. 2002 Jul;65(7):1001-5
references.pmid: 12141860
references.citation: Anticancer Drugs. 2001 Jun;12(5):475-83
references.pmid: 11395576
references.citation: Cancer Res. 2000 Jul 15;60(14):3807-12
references.pmid: 10919654
references.citation: Prostate. 2003 Feb 1;54(2):112-24
references.pmid: 12497584
references.citation: Leuk Res. 1995 Aug;19(8):549-56
references.pmid: 7658701
references.citation: Jpn J Cancer Res. 1994 Jun;85(6):645-51
references.pmid: 8063619
references.citation: J Biol Chem. 2000 Sep 8;275(36):27832-7
references.pmid: 10874030
references.citation: Mol Interv. 2003 May;3(3):157-68
references.pmid: 14993422
references.citation: Mol Interv. 2008 Feb;8(1):36-49
references.pmid: 18332483
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Biochem Pharmacol. 2004 Feb 15;67(4):727-33
references.pmid: 14757172
references.citation: Leuk Res. 1997 Sep;21(9):875-83
references.pmid: 9393603